CN108159413B - Freeze-dried live vaccine for animals and preparation method thereof - Google Patents
Freeze-dried live vaccine for animals and preparation method thereof Download PDFInfo
- Publication number
- CN108159413B CN108159413B CN201810024428.8A CN201810024428A CN108159413B CN 108159413 B CN108159413 B CN 108159413B CN 201810024428 A CN201810024428 A CN 201810024428A CN 108159413 B CN108159413 B CN 108159413B
- Authority
- CN
- China
- Prior art keywords
- freeze
- live vaccine
- dried
- protective agent
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The invention discloses a freeze-dried live vaccine for animals and a preparation method thereof. The invention has the following advantages and effects: the freeze-dried live vaccine for animals comprises live vaccine antigen and a freeze-dried protective agent, wherein the freeze-dried protective agent comprises an antifreeze, an antioxidant and a filling agent, the antifreeze reduces the formation of crystal water in the freeze-drying process, and the antioxidant reduces the oxidation effect in the preservation process of the freeze-dried live vaccine for animals; the chondroitin sulfate is combined with the live vaccine antigen to play a role in protecting the live vaccine antigen; the fiber adhesive protein is connected or coated on the live vaccine antigen, so that the live vaccine antigen is further protected, and the effects of good stability, good heat resistance, long storage time and convenience in transportation and storage are achieved.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a freeze-dried live vaccine for animals and a preparation method thereof.
Background
The vaccine refers to a biological product which is prepared from various pathogenic microorganisms and used for vaccination, and comprises a live vaccine and a dead vaccine. Live vaccines are live microbial preparations, also called attenuated live vaccines, which are prepared by artificially attenuating pathogens or by screening natural sources for avirulent or virulent strains of a pathogen. The live vaccine is inoculated into an animal body, the disease cannot be caused, but the pathogen can initiate the immune response of the organism to play a role in obtaining long-term or lifetime protection, and compared with the inactivated vaccine, the live vaccine has strong immunity and long acting time.
In animal vaccines, live vaccines account for a considerable proportion, and with the rapid development of animal husbandry, the amount and type of vaccine used in animals has increased. At present, the live vaccine is stored in a freeze-dried powder form, the live vaccine is added into a freeze-drying protective agent for freeze-drying treatment to obtain the freeze-dried live vaccine, and the freeze-drying protective agent commonly used at present mainly comprises milk, cane sugar, gelatin and the like, has simple components and poor protection function, and leads to short storage life and poor stability of the freeze-dried live vaccine.
Disclosure of Invention
The invention aims to provide a freeze-dried live vaccine for animals, which has the effects of good stability and long storage time.
The technical purpose of the invention is realized by the following technical scheme: a lyophilized live vaccine for animals comprises live vaccine antigen and lyophilized protectant, wherein the lyophilized protectant comprises fibronectin and riboflavin.
By adopting the technical scheme, the freeze-dried live vaccine for the animal comprises the live vaccine antigen and the freeze-dried protective agent, the live vaccine antigen is attenuated after attenuation treatment, the toxicity is weakened, the live vaccine antigen is inoculated into the animal body and cannot cause diseases, but pathogens can grow and reproduce in the animal body to trigger the immune response of the organism, so that the effect of obtaining long-term protection is achieved, and the effects of strong immunity and long protection time are achieved. However, the freeze-dried live vaccine is a live microbial preparation, so that the freeze-dried live vaccine has high requirements on the environment in the preservation process and has poor stability.
Fibronectin and riboflavin are added into the freeze-drying protective agent, the fibronectin is a high molecular glycoprotein and has multiple biological functions, one of the most basic functions of the fibronectin is to promote the adhesion growth of cells, and the cell adhesion is a necessary condition for maintaining the body structure and finishing the cell growth. The fibronectin has high-affinity binding sites with collagen, cells, protein and the like, the fibronectin is added into the freeze-drying protective agent, and live vaccine antigens are adhered to the fibronectin and are mutually connected through the fibronectin, so that the live vaccine antigens are protected, and the stability and the heat resistance of the freeze-dried live vaccine for animals are improved.
The riboflavin is an isoalloxazine derivative of a ribitol side chain, is an orange yellow crystal, and is dispersed in the freeze-drying protective agent, so that the adhesion of the fibronectin or the coating of the live vaccine antigen is promoted, and the protection effect of the fibronectin on the live vaccine antigen is improved.
The invention is further provided with: histidine is included in the lyoprotectant.
By adopting the technical scheme, the histidine is dissolved in water, has imidazolyl and is dispersed in the freeze-drying protective agent, so that the effect of protecting live vaccine antigens can be achieved.
The invention is further provided with: the freeze-drying protective agent comprises chondroitin sulfate.
By adopting the technical scheme, the chondroitin sulfate is a glycosaminoglycan which is covalently connected on protein to form proteoglycan and is widely distributed on an extracellular matrix and a cell surface of an animal tissue, the sugar chain consists of alternating glucuronic acid and N-acetylgalactosamine disaccharide units and is connected to the serine residue of the core protein through a similar sugar chain connecting region, the protein on the live vaccine antigen is combined on the chondroitin sulfate, the chondroitin sulfate has better heat resistance, and the chondroitin sulfate not only can play a role in protecting the live vaccine antigen in freeze drying, but also can further improve the heat resistance and the stability of the live vaccine antigen.
The invention is further provided with: the lyoprotectant includes a silk peptide therein.
By adopting the technical scheme, the silk peptide is a degradation product of silk protein, is obtained by hydrolyzing natural silk under proper conditions, is a faint yellow liquid, has a plurality of hydrophilic groups on the structure of the silk peptide, has a good moisturizing effect, can keep a small amount of moisture after freeze drying of the freeze-dried live vaccine for animals, has good moisturizing performance, improves the heat resistance and stability of the freeze-dried live vaccine for animals, prolongs the storage life, and is convenient to transport and store.
The invention is further provided with: the freeze-drying protective agent comprises an antifreezing agent, and the antifreezing agent is one or more of glycerol, dimethyl sulfoxide and sucrose.
By adopting the technical scheme, the antifreezing agent is used for preventing and reducing the formation of crystal water in the freezing process so as to protect the biological activity of the live vaccine antigen, and the antifreezing agent is one or more of glycerol, dimethyl sulfoxide and sucrose.
The invention is further provided with: the freeze-drying protective agent comprises an antioxidant and a filling agent, wherein the antioxidant is vitamin D or vitamin E, and the filling agent is one or more of mannitol, lactose and gelatin.
By adopting the technical scheme, the antioxidant can prevent the oxidation effect of the freeze-dried live vaccine for animals in the storage process and prolong the storage life of the freeze-dried live vaccine for animals. In the freeze-drying process, part of substances are easy to sublimate and scatter along with water vapor, a filling agent is added into the freeze-drying protective agent, and the filling agent is selected from one of mannitol, lactose and gelatin, so that the sublimation and scattering of the substances in the freeze-dried live vaccine for animals along with the water vapor are reduced.
The invention is further provided with: the live vaccine antigen is rinderpest virus or hog cholera virus or bacillus anthracis.
By adopting the technical scheme, the rinderpest virus is a virus of morbillivirus of Paramyxoviridae, and has polymorphism and an envelope. Cattle are most susceptible to rinderpest virus, and other animals such as goats, sheep, camels, deer and pigs can also develop diseases, rinderpest is often epidemic in outbreak, and diseased cattle are the main transmission source. The classical swine fever virus is a pathogen of classical swine fever, and harms pigs and wild pigs, and other animals do not attack the swine fever virus. Hog cholera is an acute, hot and highly contagious infectious disease and is mainly characterized by high temperature and microvascular deformation causing systemic hemorrhage, necrosis and choking. The swine fever has serious harm to pigs, and can cause great loss in the pig industry. Bacillus anthracis belongs to the genus Bacillus and is responsible for some livestock. The pathogenic bacteria of the anthrax of wild animals and human beings are susceptible to infection of cattle, sheep and pigs, and the bacillus anthracis has great harm to the public health and the economic development of society.
Another object of the present invention is to provide a method for preparing the lyophilized live vaccine for animals, which comprises the following steps: step one, preparing a freeze-drying protective agent, namely adding each component in the freeze-drying protective agent into sterilized water and uniformly mixing to obtain the freeze-drying protective agent; adding a live vaccine antigen, and adding the live vaccine antigen into a freeze-drying protective agent; and step three, freeze drying, namely placing the freeze-drying protective agent containing the live vaccine antigen in the step two into a freeze dryer for freeze drying treatment to obtain the freeze-dried live vaccine for the animal.
In conclusion, the invention has the following beneficial effects: the freeze-dried live vaccine for animals comprises live vaccine antigen and a freeze-dried protective agent, wherein the freeze-dried protective agent comprises an antifreeze, an antioxidant and a filling agent, the antifreeze reduces the formation of crystal water in the freeze-drying process, and the antioxidant reduces the oxidation effect in the preservation process of the freeze-dried live vaccine for animals; the chondroitin sulfate is combined with the live vaccine antigen to play a role in protecting the live vaccine antigen; the fiber adhesive protein is connected or coated on the live vaccine antigen, so that the live vaccine antigen is further protected, and the effects of good stability, good heat resistance, long storage time and convenience in transportation and storage are achieved.
Detailed Description
Example 1: a freeze-dried live vaccine for animal is composed of live vaccine antigen and freeze-drying protecting agent. The components and parts by weight of the lyoprotectant are shown in table 1. The antifreezing agent is glycerol, the antioxidant is vitamin D, and the bulking agent is mannitol.
The preparation method of the freeze-dried live vaccine for the animals comprises the following steps of firstly, preparing a freeze-dried protective agent, adding each component in the freeze-dried protective agent into sterilized water, and uniformly mixing to obtain the freeze-dried protective agent; adding live vaccine antigen, adding the live vaccine antigen into the freeze-drying protective agent, wherein the weight parts of the sterilized water in the freeze-drying protective agent are shown in the table 1; and step three, freeze drying, namely placing the freeze-drying protective agent containing the live vaccine antigen in the step two into a freeze dryer for freeze drying treatment to obtain the freeze-dried live vaccine for the animal.
Example 2: a freeze-dried live vaccine for animals is different from that in example 1 in that the antifreezing agent is dimethyl sulfoxide, the antioxidant is vitamin E, and the bulking agent is lactose. The components and parts by weight of the lyoprotectant are shown in table 1.
Example 3: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 1 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Example 4: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 2 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Example 5: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 1 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Example 6: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 2 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Example 7: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 1 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Example 8: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 2 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Example 9: a freeze-dried live vaccine for animal is composed of live vaccine antigen and freeze-drying protecting agent. The components and parts by weight of the lyoprotectant are shown in table 1. The antifreezing agent is glycerol and sucrose, and the weight parts of the glycerol are as follows: sucrose 3:1, antioxidant vitamin D, and bulking agent gelatin.
The preparation method of the freeze-dried live vaccine for the animals comprises the following steps of preparing a freeze-dried protective agent, adding each component in the freeze-dried protective agent into sterilized water, and uniformly mixing to obtain the freeze-dried protective agent, wherein the parts by weight of the sterilized water in the freeze-dried protective agent are shown in table 1; adding a live vaccine antigen, and adding the live vaccine antigen into a freeze-drying protective agent; and step three, freeze drying, namely placing the freeze-drying protective agent containing the live vaccine antigen in the step two into a freeze dryer for freeze drying treatment to obtain the freeze-dried live vaccine for the animal.
Example 10: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 11: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 12: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 13: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 14: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 15: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 16: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 17: a freeze-dried live vaccine for animal is composed of live vaccine antigen (Bacillus anthracis), freeze-drying protecting agent, and freeze-drying protecting agent. The components and parts by weight of the lyoprotectant are shown in table 1. The antifreezing agent is dimethyl sulfoxide and sucrose, and the weight parts of the dimethyl sulfoxide are as follows: sucrose 3:1, antioxidant vitamin E, and bulking agent gelatin.
The preparation method of the freeze-dried live vaccine for the animals comprises the following steps of preparing a freeze-dried protective agent, adding each component in the freeze-dried protective agent into sterilized water, and uniformly mixing to obtain the freeze-dried protective agent, wherein the parts by weight of the sterilized water in the freeze-dried protective agent are shown in table 1; adding a live vaccine antigen, and adding the live vaccine antigen into a freeze-drying protective agent; and step three, freeze drying, namely placing the freeze-drying protective agent containing the live vaccine antigen in the step two into a freeze dryer for freeze drying treatment to obtain the freeze-dried live vaccine for the animal.
Example 18: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 19: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 20: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 21: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 22: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 23: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Example 24: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Comparative example 1: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 1 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Comparative example 2: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 1 in that the components and parts by weight in the freeze-dried protective agent are shown in Table 1.
Comparative example 3: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Comparative example 4: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 9 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Comparative example 5: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
Comparative example 6: a freeze-dried live vaccine for animals is different from the freeze-dried live vaccine in example 17 in that the components and parts by weight of the freeze-dried protective agent are shown in Table 1.
TABLE 1
Thermal stability test: 4 portions of the freeze-dried live vaccines for animals in examples 1 to 16 and comparative examples 1 to 4 were taken, placed at-20 ℃ for 24, 30, 36, 40, 44 and 48 months, placed at 2 to 8 ℃ for 9, 12, 15, 18, 20, 22, 24 and 26 months, and placed at 37 ℃ for 5, 7, 14, 21 and 28 days, and the titer of the freeze-dried live vaccine for animals (unit: logCCID) was determined by sampling50mL) and the test results are listed in tables 2 to 4.
The lyophilized live vaccines for animals of examples 17 to 24 and comparative examples 5 to 6 were taken, placed at 37 ℃, and the titer retention time of the lyophilized live vaccine for animals was measured, and the test results are listed in table 5.
TABLE 2
TABLE 3
TABLE 4
TABLE 5
The specific embodiments are only for explaining the present invention, and the present invention is not limited thereto, and those skilled in the art can make modifications without inventive contribution to the present embodiments as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present invention.
Claims (6)
1. A freeze-dried live vaccine for animals comprises live vaccine antigen and freeze-drying protective agent, wherein the freeze-drying protective agent comprises fibronectin, riboflavin, antifreeze, antioxidant and bulking agent;
the antifreezing agent is one or more of glycerol, dimethyl sulfoxide and sucrose;
the antioxidant is vitamin D or vitamin E, and the bulking agent is one or more of mannitol, lactose, and gelatin.
2. A lyophilized live vaccine for animals according to claim 1, characterized in that: histidine is included in the lyoprotectant.
3. A lyophilized live vaccine for animals according to claim 1, characterized in that: the freeze-drying protective agent comprises chondroitin sulfate.
4. A lyophilized live vaccine for animals according to claim 1, characterized in that: the lyoprotectant includes a silk peptide therein.
5. A lyophilized live vaccine for animals according to claim 1, characterized in that: the live vaccine antigen is rinderpest virus or hog cholera virus or bacillus anthracis.
6. A method for preparing a lyophilized live vaccine for animals according to claims 1-5, wherein: step one, preparing a freeze-drying protective agent, namely adding each component in the freeze-drying protective agent into sterilized water and uniformly mixing to obtain the freeze-drying protective agent; adding a live vaccine antigen, and adding the live vaccine antigen into a freeze-drying protective agent; and step three, freeze drying, namely placing the freeze-drying protective agent containing the live vaccine antigen in the step two into a freeze dryer for freeze drying treatment to obtain the freeze-dried live vaccine for the animal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810024428.8A CN108159413B (en) | 2018-01-10 | 2018-01-10 | Freeze-dried live vaccine for animals and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810024428.8A CN108159413B (en) | 2018-01-10 | 2018-01-10 | Freeze-dried live vaccine for animals and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108159413A CN108159413A (en) | 2018-06-15 |
| CN108159413B true CN108159413B (en) | 2021-07-06 |
Family
ID=62518072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810024428.8A Active CN108159413B (en) | 2018-01-10 | 2018-01-10 | Freeze-dried live vaccine for animals and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108159413B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108703952B (en) * | 2018-08-16 | 2021-05-07 | 张志刚 | Freeze-drying protective agent for swine fever oral attenuated freeze-dried vaccine and application |
| CN110801436B (en) * | 2019-11-19 | 2021-06-22 | 畜科生物工程有限公司 | Porcine transmissible gastroenteritis and porcine epidemic diarrhea bivalent live vaccine freeze-drying protective agent and bivalent live vaccine |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| CN106860861A (en) * | 2017-03-03 | 2017-06-20 | 北京博辉瑞进生物科技有限公司 | A kind of immunopotentiating composition, preparation method and applications |
| CN107029224A (en) * | 2017-03-03 | 2017-08-11 | 北京博辉瑞进生物科技有限公司 | A kind of antitumor collagen compositions of Immune-enhancing effect, preparation method and applications |
| CN107174663A (en) * | 2017-05-22 | 2017-09-19 | 杭州洪晟生物技术股份有限公司 | Vaccine freeze-drying protective agent |
| CN107260570A (en) * | 2017-06-14 | 2017-10-20 | 南京仯素生物科技有限公司 | A kind of mescenchymal stem cell factor composition and its production and use |
-
2018
- 2018-01-10 CN CN201810024428.8A patent/CN108159413B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| CN106860861A (en) * | 2017-03-03 | 2017-06-20 | 北京博辉瑞进生物科技有限公司 | A kind of immunopotentiating composition, preparation method and applications |
| CN107029224A (en) * | 2017-03-03 | 2017-08-11 | 北京博辉瑞进生物科技有限公司 | A kind of antitumor collagen compositions of Immune-enhancing effect, preparation method and applications |
| CN107174663A (en) * | 2017-05-22 | 2017-09-19 | 杭州洪晟生物技术股份有限公司 | Vaccine freeze-drying protective agent |
| CN107260570A (en) * | 2017-06-14 | 2017-10-20 | 南京仯素生物科技有限公司 | A kind of mescenchymal stem cell factor composition and its production and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108159413A (en) | 2018-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6896802B2 (en) | Dry formulation of vaccine that is stable at room temperature | |
| ES2228540T3 (en) | METHOD FOR CONSERVING BIOLOGICALLY ACTIVE MATERIAL. | |
| CN108159413B (en) | Freeze-dried live vaccine for animals and preparation method thereof | |
| JPS61502334A (en) | Cell surface proteins and their production and use | |
| CN101947321B (en) | Heat-resisting and freeze-drying protector for live vaccine and preparation method thereof as well as live newcastle disease vaccine | |
| CN107184985B (en) | Heat-resistant freeze-drying protective agent for newcastle disease live vaccine (Lasota strain) | |
| CN101474410A (en) | Heat-resisting lyophilized protecting agent of live vaccine for animal and preparation method thereof | |
| CN105999281B (en) | Birds live virus freeze drying protectant, preparation method and application | |
| CN107174663B (en) | Vaccine freeze-drying protective agent | |
| CN100418580C (en) | Heat resistant freeze drying protectant for chicken Newcastle disease live vaccine and its prepn and application | |
| CN104548084A (en) | Vaccine composition for preventing and controlling porcine reproductive and respiratory syndrome and having broad-spectrum mucosal immunity function and application of vaccine composition | |
| CN103656660B (en) | A kind of animal heat-resisting lyophilized protecting agent of live vaccine, its preparation method and application | |
| CN104248761B (en) | A kind of vaccine combination and its preparation method and application | |
| ES2269672T3 (en) | VACCINE AGAINST MYCOPLASMA INACTIVATED BY SAPONINA. | |
| CN1321694C (en) | Freezedrying type vaccine of AIDS recombined poxvirus with Ankara gene stock carrier, and preparation method | |
| CN108938574B (en) | Freeze-dried heat-resistant protective agent for porcine pseudorabies live vaccine, and preparation method and application thereof | |
| KR960003606B1 (en) | Vaccines for fowl colibacillosis | |
| KR100622399B1 (en) | Vaccine Comprising the Mixture of Inactivated TGEV and PEDV, and Preparation Method thereof | |
| JP2020500913A (en) | Oral vaccine against ruminant respiratory disease containing polyvinylpyrrolidone | |
| RU2406531C1 (en) | Associated vaccine against streptoccocosis, pseudomonosis and enterococcus infection in nutria | |
| CN109432017B (en) | Heat-resistant freeze-drying protective agent for henpox and application thereof | |
| RU2316344C1 (en) | Associated vaccine against colibacteriosis, salmonellosis, streptococcosis and enterococcal infection in nutrias | |
| CN1211122C (en) | Heat-resisting lyophilized protectant for swine fever lapinized hyoptoxicity calf testicular cell vaccine and preparing process | |
| RU2301078C1 (en) | Mixed vaccine against coli-bacteriosis, salmonellosis and entrococcus infection in nutria | |
| RU2301680C1 (en) | Mixed vaccine against streptococcosus and enterococcal infection in nutria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |